/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company has a market capitalization of $83.7 billion and develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases, as well as cancer and more.
The company's shares have outperformed the broader market over the past year and in 2026. REGN stock has surged 14.1% over the past 52 weeks and 1.4% on a YTD basis. In comparison, the S&P 500 Index ($SPX) has returned 11.7% over the past year and grown marginally in 2026.